U.S. Stock Market News: Novo Nordisk (NVO.US) falls nearly 6% and terminates partnership with Hims & Hers

According to the Wisdom Financial APP, on Monday, Novo Nordisk (NVO.US) fell nearly 6% to $69.40. In terms of news, Novo Nordisk announced on June 23 that it would terminate its partnership with the telemedicine company Hims & Hers due to concerns about their sales and promotion of cheap generic versions of Wegovy. Novo Nordisk stated that Hims & Hers did not comply with relevant laws and was suspected of selling compound drugs on a large scale under the guise of "personalization". The company also accused Hims & Hers of engaging in "misleading" marketing practices that jeopardize patient safety.